Compare ARK Fintech Innovation ETF (ARKF) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Koninklijke Philips NV — how do they compare? ARK Fintech Innovation ETF trades at $41.45, while Koninklijke Philips NV trades at $27.4 (market cap $26.63B). The key difference: Koninklijke Philips NV pays a 3.7% dividend while ARK Fintech Innovation ETF pays none, and Koninklijke Philips NV is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | PHG | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $32.91 |
52-Week Low | $36.14 | $24.03 |
Market Cap | — | $26.63B |
Enterprise Value | — | $32.90B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $41.63, up 0.43% with bullish technical signals from moving averages and strong trend strength (ADX 39.69). The stock faces resistance at $42 with support at $41. Recent coverage highlights institutional interest in Cathie Wood's and Bill Ackman's overlapping investments in Magnificent Seven stocks.
The ETF's outlook is supported by technical momentum but lacks fundamental financial data disclosure. Key risks include market volatility and dependency on top holdings performance. Institutional overlap suggests confidence in selected growth stocks, though valuation metrics remain undisclosed.
Royal Philips (PHG) trades at $27.40, up 0.51% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight growth initiatives. Analyst consensus leans neutral with 40.9% buy ratings amid stable revenue around $17.8 billion.
PHG presents a recovery story with margin expansion and AI innovation driving upside potential, though execution risks and debt levels near 25% of assets warrant caution. The stock's 24.1 P/E appears reasonable if earnings growth sustains, but investors should monitor competitive pressures in healthcare technology and macroeconomic impacts on capital spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
